Aldeyra Therapeutics, Inc.

ALDXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1341235

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$48.2M	$29.5M	$47.3M	$44.9M	$24.7M
Operating Income (Loss)	-$60.1M	-$42.8M	-$62.7M	-$56.2M	-$36.4M
Interest Expense	—	—	$1.7M	$1.7M	$1.9M
Nonoperating Income (Expense)	$4.3M	$5.3M	$655.4K	-$1.6M	-$1.6M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	-$38.0M
Income Tax Expense (Benefit)	$1.0K	$0.00	$0.00	$0.00	-$479.3K
Net Income (Loss) Attributable to Parent	-$55.9M	-$37.5M	-$62.0M	-$57.8M	-$37.6M
Earnings Per Share, Basic	-$0.94	-$0.64	-$1.06	-$1.07	—
Earnings Per Share, Diluted	-$0.94	-$0.64	-$1.06	-$1.07	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$104.6M	$148.3M	$181.3M	$233.1M	$83.4M
Assets, Current	$104.1M	$147.8M	$181.0M	$232.8M	$83.1M
Cash and Cash Equivalents, at Carrying Value	$54.5M	$54.5M	$144.4M	$229.8M	$77.9M
Liabilities	$33.6M	$28.5M	$30.3M	$27.4M	$23.8M
Liabilities, Current	$18.6M	$22.3M	$15.4M	$11.8M	$12.4M
Long-term Debt	$15.3M	$15.3M	$15.3M	$16.3M	$16.0M
Accounts Payable, Current	$180.5K	$1.3M	$133.6K	$1.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$43.2M	-$30.3M	-$56.6M	-$42.6M	-$37.5M
Net Cash Provided by (Used in) Investing Activities	-$44.9M	$30.0M	-$30.0M	-$7.8K	$29.0M
Net Cash Provided by (Used in) Financing Activities	-$171.4K	-$1.3M	$1.2M	$194.5M	$41.9M
Payments to Acquire Property, Plant, and Equipment	—	—	$16.3K	$7.8K	$7.8K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)